Hydroxyurea alters circulating monocyte subsets and dampens its inflammatory potential in sickle cell anemia patients

Sickle cell anemia (SCA) is a hemolytic disease in which vaso-occlusion is an important pathophysiological mechanism. The treatment is based on hydroxyurea (HU), which decreases leukocyte counts and increases fetal hemoglobin synthesis. Different cell types are thought to contribute to vaso-occlusio...

Descripción completa

Detalles Bibliográficos
Autores principales: Guarda, Caroline C., Silveira-Mattos, Paulo S. M., Yahouédéhou, Sètondji C. M. A., Santiago, Rayra P., Aleluia, Milena M., Figueiredo, Camylla V. B., Fiuza, Luciana M., Carvalho, Suellen P., Oliveira, Rodrigo M., Nascimento, Valma M. L., Luz, Nívea F., Borges, Valéria M., Andrade, Bruno B., Gonçalves, Marilda S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6794261/
https://www.ncbi.nlm.nih.gov/pubmed/31616024
http://dx.doi.org/10.1038/s41598-019-51339-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6794261/
https://www.ncbi.nlm.nih.gov/pubmed/31616024
http://dx.doi.org/10.1038/s41598-019-51339-x

Ejemplares similares